ScreenerHero

TKNO Alpha Teknova, Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · teknova.com
8.710USD-0.46%Mkt Cap: 467.62M $P/E: —

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary …

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$66.23BUSDP/E 25.7
TAK
Takeda Pharmaceutical Company Limited
$58.68BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.70BUSDP/E 65.3
GALD
Galderma Group AG
$43.27BUSDP/E 56.1
HLN
Haleon plc
$39.67BUSDP/E 18.4
SDZ
Sandoz Group AG
$34.93BUSDP/E 60.5
HLN
Haleon plc
$32.73BUSDP/E 19.0
ZOE
Zoetis Inc.
$28.56BUSDP/E 12.2
ZTS
Zoetis Inc.
$29.57BUSDP/E 11.8
UTHR
United Therapeutics Corporation
$23.38BUSDP/E 19.5
VTRS
Viatris Inc.
$20.09BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.43BUSDP/E 112.9
NBIX
Neurocrine Biosciences, Inc.
$14.58BUSDP/E 21.0
IPN
Ipsen S.A.
$12.99BUSDP/E 23.5
ELAN
Elanco Animal Health Incorporated
$11.17BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.22BUSDP/E 27.9
KRK
Krka, d. d.
$8.66BUSDP/E 19.3
ALKS
Alkermes plc
$6.95BUSDP/E 109.1
HIMS
Hims & Hers Health, Inc.
$6.89BUSD
AMRX
Amneal Pharmaceuticals, Inc.
$6.84BUSDP/E 40.1

Key Statistics

Company
Market Cap467.62M USD
Enterprise Value479.74M USD
Revenue (TTM)43.70M USD
Gross Profit13.44M USD
Net Income (TTM)-17.26M USD
Revenue/Share0.82 USD
Last Price8.710 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees158
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-46.05
PEG—
EV/EBITDA-53.47
EV/Revenue10.98
P/S10.75
P/B7.50
EPS (TTM)-0.30
EPS (Forward)-0.19
52W Range
1.91090% of range9.472
52W High9.472 USD
52W Low1.910 USD
Profitability
Gross Margin33.17%
Oper. Margin-23.72%
EBITDA Margin-20.53%
Profit Margin-42.59%
ROE-25.09%
ROA-16.66%
Growth
Revenue Growth18.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-8.65M USD
CapEx (TTM)1.15M USD
FCF Margin-1.68%
FCF Yield-0.16%
Net Debt9.97M USD
Net Debt/EBITDA-1.11
Balance Sheet
Debt/Equity0.41
Current Ratio4.49
Quick Ratio3.32
Book Value/Sh1.17 USD
Cash/Share0.33 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)9.000 USD
Upside (mean)+3.3%
Target Range7.000 USD – 12.00 USD
7.000+3.3% to mean12.00
# Analysts6
Ownership
Shares Out.53.69M
Float10.99M
Insiders9.31%
Institutions87.35%
Short Interest
Short Ratio8.0d
Short % Float14.37%
Short % Out.2.94%
Shares Short1.58M
Short (prev mo.)1.59M
Technical
SMA 507.206 (+20.9%)
SMA 2004.560 (+91.0%)
Beta0.86
S&P 52W Chg16.45%
Avg Vol (30d)271.76K
Avg Vol (10d)345.50K
Technical Indicators
RSI (14)63.8
MACD0.5748
MACD Signal0.6140
MACD Hist.-0.0392
BB Upper10.26 USD
BB Middle8.185 USD
BB Lower6.111 USD
BB Width50.67%
ATR (14)0.5239 USD
Vol Ratio (20d)0.96x